|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:CACNA2D1-NAALADL2 (FusionGDB2 ID:HG781TG254827) |
Fusion Gene Summary for CACNA2D1-NAALADL2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: CACNA2D1-NAALADL2 | Fusion gene ID: hg781tg254827 | Hgene | Tgene | Gene symbol | CACNA2D1 | NAALADL2 | Gene ID | 781 | 254827 |
Gene name | calcium voltage-gated channel auxiliary subunit alpha2delta 1 | N-acetylated alpha-linked acidic dipeptidase like 2 | |
Synonyms | CACNA2|CACNL2A|CCHL2A|LINC01112|lncRNA-N3 | - | |
Cytomap | ('CACNA2D1')('NAALADL2') 7q21.11 | 3q26.31 | |
Type of gene | protein-coding | protein-coding | |
Description | voltage-dependent calcium channel subunit alpha-2/delta-1calcium channel, L type, alpha 2 polypeptidecalcium channel, voltage-dependent, alpha 2/delta subunit 1dihydropyridine-sensitive L-type, calcium channel alpha-2/delta subunitvoltage-gated calciu | inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2N-acetylated alpha-linked acidic dipeptidase 2NAALADase L2glutamate carboxypeptidase II-type non-peptidase homologue | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | Q58DX5 | |
Ensembl transtripts involved in fusion gene | ENST00000356253, ENST00000356860, ENST00000423588, ENST00000464354, ENST00000535308, | ||
Fusion gene scores | * DoF score | 6 X 8 X 4=192 | 21 X 16 X 9=3024 |
# samples | 9 | 24 | |
** MAII score | log2(9/192*10)=-1.09310940439148 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(24/3024*10)=-3.65535182861255 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: CACNA2D1 [Title/Abstract] AND NAALADL2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | CACNA2D1(81964451)-NAALADL2(175455094), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | CACNA2D1-NAALADL2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CACNA2D1-NAALADL2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CACNA2D1 | GO:0006816 | calcium ion transport | 1309651|11160515 |
Hgene | CACNA2D1 | GO:0051924 | regulation of calcium ion transport | 1309651 |
Fusion gene breakpoints across CACNA2D1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across NAALADL2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | HNSC | TCGA-CN-4723-01A | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
ChimerDB4 | HNSC | TCGA-CN-4723 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
Top |
Fusion Gene ORF analysis for CACNA2D1-NAALADL2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-intron | ENST00000356253 | ENST00000473253 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
5CDS-intron | ENST00000356860 | ENST00000473253 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
5CDS-intron | ENST00000423588 | ENST00000473253 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
In-frame | ENST00000356253 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
In-frame | ENST00000356860 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
In-frame | ENST00000423588 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
intron-3CDS | ENST00000464354 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
intron-3CDS | ENST00000535308 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
intron-intron | ENST00000464354 | ENST00000473253 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
intron-intron | ENST00000535308 | ENST00000473253 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000356860 | CACNA2D1 | chr7 | 81964451 | - | ENST00000454872 | NAALADL2 | chr3 | 175455094 | + | 3562 | 633 | 339 | 1124 | 261 |
ENST00000356253 | CACNA2D1 | chr7 | 81964451 | - | ENST00000454872 | NAALADL2 | chr3 | 175455094 | + | 3479 | 550 | 256 | 1041 | 261 |
ENST00000423588 | CACNA2D1 | chr7 | 81964451 | - | ENST00000454872 | NAALADL2 | chr3 | 175455094 | + | 3480 | 551 | 257 | 1042 | 261 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000356860 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + | 0.000458339 | 0.99954164 |
ENST00000356253 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + | 0.000417262 | 0.9995827 |
ENST00000423588 | ENST00000454872 | CACNA2D1 | chr7 | 81964451 | - | NAALADL2 | chr3 | 175455094 | + | 0.00041797 | 0.999582 |
Top |
Fusion Genomic Features for CACNA2D1-NAALADL2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
CACNA2D1 | chr7 | 81964450 | - | NAALADL2 | chr3 | 175455093 | + | 3.36E-08 | 1 |
CACNA2D1 | chr7 | 81964450 | - | NAALADL2 | chr3 | 175455093 | + | 3.36E-08 | 1 |
CACNA2D1 | chr7 | 81964450 | - | NAALADL2 | chr3 | 175455093 | + | 3.36E-08 | 1 |
CACNA2D1 | chr7 | 81964450 | - | NAALADL2 | chr3 | 175455093 | + | 3.36E-08 | 1 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for CACNA2D1-NAALADL2 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:81964451/chr3:175455094) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | NAALADL2 |
FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: May be catalytically inactive. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356253 | - | 3 | 39 | 253_430 | 98 | 1104.0 | Domain | VWFA |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356253 | - | 3 | 39 | 446_556 | 98 | 1104.0 | Domain | Note=Cache |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356860 | - | 3 | 39 | 253_430 | 98 | 1092.0 | Domain | VWFA |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356860 | - | 3 | 39 | 446_556 | 98 | 1092.0 | Domain | Note=Cache |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356253 | - | 3 | 39 | 259_263 | 98 | 1104.0 | Motif | Note=MIDAS-like motif |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356860 | - | 3 | 39 | 259_263 | 98 | 1092.0 | Motif | Note=MIDAS-like motif |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356253 | - | 3 | 39 | 1095_1103 | 98 | 1104.0 | Topological domain | Cytoplasmic |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356253 | - | 3 | 39 | 25_1073 | 98 | 1104.0 | Topological domain | Extracellular |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356860 | - | 3 | 39 | 1095_1103 | 98 | 1092.0 | Topological domain | Cytoplasmic |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356860 | - | 3 | 39 | 25_1073 | 98 | 1092.0 | Topological domain | Extracellular |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356253 | - | 3 | 39 | 1074_1094 | 98 | 1104.0 | Transmembrane | Helical |
Hgene | CACNA2D1 | chr7:81964451 | chr3:175455094 | ENST00000356860 | - | 3 | 39 | 1074_1094 | 98 | 1092.0 | Transmembrane | Helical |
Tgene | NAALADL2 | chr7:81964451 | chr3:175455094 | ENST00000454872 | 10 | 14 | 143_795 | 632 | 796.0 | Topological domain | Extracellular | |
Tgene | NAALADL2 | chr7:81964451 | chr3:175455094 | ENST00000454872 | 10 | 14 | 1_121 | 632 | 796.0 | Topological domain | Cytoplasmic | |
Tgene | NAALADL2 | chr7:81964451 | chr3:175455094 | ENST00000454872 | 10 | 14 | 122_142 | 632 | 796.0 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein |
Top |
Fusion Gene Sequence for CACNA2D1-NAALADL2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>12355_12355_1_CACNA2D1-NAALADL2_CACNA2D1_chr7_81964451_ENST00000356253_NAALADL2_chr3_175455094_ENST00000454872_length(transcript)=3479nt_BP=550nt CGGCGGAGGCAAGGCGGCCGCGGCGCGGAGCAGCCGACGCACGCTAGTGGGTCCGCCCGCCACCGCCCCTTCCTCGGCGTCCGCTCCCGC CCTTGCCGTCCCCCGCGCGGCTCCGCGCCTCGGGCCCCGGGCGCAGCCAGCCCTCCAGACGCCCGCGGTCCCGGCGGCGTGTGCTGCTCT TCCTCCGCCCGCGGTTTCCAGCGCCGCTCCTTCCCCCGCTTGGGCAGGGAGGGGGCATTGATCTTCGATCGCGAAGATGGCTGCTGGCTG CCTGCTGGCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGCCCCTCGTCGGAGGAGCCGTTCCCTTCGGCCGTCACTATCAAATC ATGGGTGGATAAGATGCAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATTTATGAGAAATATCA AGATTTGTATACTGTGGAACCAAATAATGCACGCCAGCTGGTAGAAATTGCAGCCAGGGATATTGAGAAACTTCTGAGCAACAGATCTAA AGCCCTGGTGCTCTCAGGAGAAGTGATTTTGCAAATTGCCAACGAACCTGTTCTGCCCTTTAATGCACTTGATATAGCTTTAGAAGTTCA AAACAACCTTAAAGGTGATCAACCCAACACTCATCAACTGTTAGCCATGGCGTTACGCCTGCGGGAGAGTGCTGAACTTTTTCAGTCTGA TGAGATGCGACCTGCTAATGATCCCAAGGAGAGAGCACCCATCCGCATCCGGATGCTGAATGACATTCTCCAAGACATGGAGAAAAGCTT TCTGGTAAAGCAGGCACCACCAGGTTTTTATAGAAACATCCTCTACCACCTTGATGAAAAGACAAGCCGGTTTTCAATACTTATAGAGGC TTGGGAACACTGCAAACCCCTTGCATCAAATGAGACCCTTCAAGAAGCCCTGTCAGAGGTGTTGAACAGCATTAATTCAGCTCAGGTTTA CTTCAAAGCAGGACTTGATGTGTTCAAGAGTGTCTTGGATGGGAAGAATTGAGAAAACTCTGAGCATTTTTAAAAGTTTGTTTACAATTC CACAAGCAAAAGCTCTAATTTAACCAGATTTTCTGACATTGAAGGCTTATTTTCCCCAATGGCTTTTTGACAAGTATAAAGCTATTATTA CATTGTATTTTTTAAATGTAAATATAGAAAGAACATTTTGCACATTTAATATTTTTCTTATATCTACATTTCTGAATATGTAAAGCAAGT TATTGAAATAGGACTTAAGAATTACCTATTAAAAAGAAATCTGATATATAAAAATATGTACTATTTTAAGGAAAAATTTCCAAGAAGTTC TGGACTATCTTTGTTCCTATGGGGAGGGCATATAGGAACACAGTTTATTCTCTCTGATAGAGCTATTAATGACTTAGTTTCTGTAAAAGA AATGGAGAGTTGATATGGTTCAGATTAACTTCACTATTAAGTGTTCAATATGAAGAATTCAAGTATTCTGACTGAGTGATTGGTTGACCT AAACCACTTTGAATGTTTCTATTTTATGAAATGAAGTTTCTCTTCTTAACACAACTAGATGTAGTAATACACTGGTTATGAAATTGTATT TTTTTAAGTATTAATGAAAAAAGAGCCATAAGCATTCCAGGAGAAAATCTCAAGGGAGCTACATAGAGCAATTTAAATGCAAATTTTTTT CCTAACAACTTACAAGGTGACTAGCTTTGAAACCCCTAATTTGCCTCAGTTGATTTTCTAAGAATTTCAGGAGTGATGTATGTCTTAAGA GGGAGAAAAAAATATTTCTTATTACTTTTTCTCTTGTTTCTGTTGGAAACACTGAAGCAGGGACTCTAAAATGAAAGCATCTCACATTGG TTTTCTTTCTTGTATCTTTTCTGAAACTCCTTGCTGTAAGGCAGCTTTCTCAGAGTACTATATATTTTCAACAGTAAAGTAGCAGAGTTT CTCTTTGAAACCCAAAATGTCTTCTAAAGAATCAAATTTCTATTTCTGCCTCTGACAAAAAGAACTTACTATGAAAGAAATAGTTGTTTT ATCAATAAAAGCCCCTTAATATTATGAAGAAACTTTTCATATTTTTTCTTCTTTATCCTTAATTGTGACTAAGATGGAAATCTAGAAAAT ATTCATGCTTCTAAGTTTCTGCAGTGTTACTGTAAGAGAGTGTCTCGTCTACACTTCAGTTCTTCTCTCATGTGGAAAACTAAGCTTTTT ATATTGACATTGCCATTGAATAGCTCTAGCAACTATTATTATTCCCCCAAACCCTAAAATTCTACCTATTAGGTGTCAGGTTAAAGTTCT AATTTATCTTTAGAAATTTATGTGAAAAATGGTTTTCCTATACTGGATAAAGCAATTCCCCTTAGGAAACATAGCCTCAGAGTATTTCAT ATAAATTTTCTCTATCTAATTCAAACATATCTCCCCATGATACACCGCCAGAGTGACATTGCAGACAGTCTGTGTATGTTTAAATTTTCA CTTTTTATGGATGAGCATAAACCTAGTCTTAGTTTAAAGGCAAACTAAAGTTGAGGGGAAATAATTAATCAATACTGATTAATTGATTTA TAAGGTTCAACACTGTCTACCCTAAATAATTTTTATATGCTCAAGGCAAAGCAGGGAATAGAGGCAATTAGCTAGATAATTCAAGCAGAA ATCCATTTTCATCGAAATTGCCTGTGTGCACATATTTTTAGATGAAAAATGAAACTACCTTACAATATTATTTTTTTAACCAATGTATTT GTTTGCAAACATTTGCCATGTTGAAGAGTGTGTATAGGAAAGGTCTAGAAATAAATAGGCTTGTGCATACCTAGGCATTCATGCTCTTTC TTCCTCTTCAGAGATCATCAGAAAAGAGGTGGGAATACACAAGCAGGTGCATGTAAGCCCAAAAGCTAGAAAGCCTTATATTTAACCAAA GGTTGATGTGTTCATTCCAGTTATTCACTTACAGATGAAACTAAAACAAATAAAGGCAAGCTATTATCAGTTTGGTAGTTCATTATTTTA GAACAAATTTCTAAATTAATTTATTCCCATAACCTACAATAGCACTGAGAACAGAAAACATGTTTCTTCTTCATTTTGTTTAAAGATTGC GTACCTAGGTAAGTCACACTGTATAGATAAAAACCTTCTTCTGTATTCCTCACCTCTAAATTATATGTTATTTGCTATTTGAAAACTGTA GTTAACTATGGTTTTTTATTAGTCTATTAAAAGATACGTGGAGATATTAAATTATACCTAAAGCAGACGTCCAACAAATTCTGTACATGC TGCTTTACATCTTTGCAACAAACCTCTTAACTAGCAGCATTATTTCTATAGTGTGATTACCTGAGGGTGCCTCCAAATGTATATCATTTC >12355_12355_1_CACNA2D1-NAALADL2_CACNA2D1_chr7_81964451_ENST00000356253_NAALADL2_chr3_175455094_ENST00000454872_length(amino acids)=261AA_BP=93 MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDIYEKYQDLYTVEPNNARQLVEIAARDIEKLL SNRSKALVLSGEVILQIANEPVLPFNALDIALEVQNNLKGDQPNTHQLLAMALRLRESAELFQSDEMRPANDPKERAPIRIRMLNDILQD -------------------------------------------------------------- >12355_12355_2_CACNA2D1-NAALADL2_CACNA2D1_chr7_81964451_ENST00000356860_NAALADL2_chr3_175455094_ENST00000454872_length(transcript)=3562nt_BP=633nt AGGGAGGAAACCGAGAGGGAGAGCGAGAGCGCGCGAGCGCCGGCGGGCTCGCCGAGGTCTGTTTCCAAAGTCGCCCTTGATGGCGGCGGA GGCAAGGCGGCCGCGGCGCGGAGCAGCCGACGCACGCTAGTGGGTCCGCCCGCCACCGCCCCTTCCTCGGCGTCCGCTCCCGCCCTTGCC GTCCCCCGCGCGGCTCCGCGCCTCGGGCCCCGGGCGCAGCCAGCCCTCCAGACGCCCGCGGTCCCGGCGGCGTGTGCTGCTCTTCCTCCG CCCGCGGTTTCCAGCGCCGCTCCTTCCCCCGCTTGGGCAGGGAGGGGGCATTGATCTTCGATCGCGAAGATGGCTGCTGGCTGCCTGCTG GCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGCCCCTCGTCGGAGGAGCCGTTCCCTTCGGCCGTCACTATCAAATCATGGGTG GATAAGATGCAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATTTATGAGAAATATCAAGATTTG TATACTGTGGAACCAAATAATGCACGCCAGCTGGTAGAAATTGCAGCCAGGGATATTGAGAAACTTCTGAGCAACAGATCTAAAGCCCTG GTGCTCTCAGGAGAAGTGATTTTGCAAATTGCCAACGAACCTGTTCTGCCCTTTAATGCACTTGATATAGCTTTAGAAGTTCAAAACAAC CTTAAAGGTGATCAACCCAACACTCATCAACTGTTAGCCATGGCGTTACGCCTGCGGGAGAGTGCTGAACTTTTTCAGTCTGATGAGATG CGACCTGCTAATGATCCCAAGGAGAGAGCACCCATCCGCATCCGGATGCTGAATGACATTCTCCAAGACATGGAGAAAAGCTTTCTGGTA AAGCAGGCACCACCAGGTTTTTATAGAAACATCCTCTACCACCTTGATGAAAAGACAAGCCGGTTTTCAATACTTATAGAGGCTTGGGAA CACTGCAAACCCCTTGCATCAAATGAGACCCTTCAAGAAGCCCTGTCAGAGGTGTTGAACAGCATTAATTCAGCTCAGGTTTACTTCAAA GCAGGACTTGATGTGTTCAAGAGTGTCTTGGATGGGAAGAATTGAGAAAACTCTGAGCATTTTTAAAAGTTTGTTTACAATTCCACAAGC AAAAGCTCTAATTTAACCAGATTTTCTGACATTGAAGGCTTATTTTCCCCAATGGCTTTTTGACAAGTATAAAGCTATTATTACATTGTA TTTTTTAAATGTAAATATAGAAAGAACATTTTGCACATTTAATATTTTTCTTATATCTACATTTCTGAATATGTAAAGCAAGTTATTGAA ATAGGACTTAAGAATTACCTATTAAAAAGAAATCTGATATATAAAAATATGTACTATTTTAAGGAAAAATTTCCAAGAAGTTCTGGACTA TCTTTGTTCCTATGGGGAGGGCATATAGGAACACAGTTTATTCTCTCTGATAGAGCTATTAATGACTTAGTTTCTGTAAAAGAAATGGAG AGTTGATATGGTTCAGATTAACTTCACTATTAAGTGTTCAATATGAAGAATTCAAGTATTCTGACTGAGTGATTGGTTGACCTAAACCAC TTTGAATGTTTCTATTTTATGAAATGAAGTTTCTCTTCTTAACACAACTAGATGTAGTAATACACTGGTTATGAAATTGTATTTTTTTAA GTATTAATGAAAAAAGAGCCATAAGCATTCCAGGAGAAAATCTCAAGGGAGCTACATAGAGCAATTTAAATGCAAATTTTTTTCCTAACA ACTTACAAGGTGACTAGCTTTGAAACCCCTAATTTGCCTCAGTTGATTTTCTAAGAATTTCAGGAGTGATGTATGTCTTAAGAGGGAGAA AAAAATATTTCTTATTACTTTTTCTCTTGTTTCTGTTGGAAACACTGAAGCAGGGACTCTAAAATGAAAGCATCTCACATTGGTTTTCTT TCTTGTATCTTTTCTGAAACTCCTTGCTGTAAGGCAGCTTTCTCAGAGTACTATATATTTTCAACAGTAAAGTAGCAGAGTTTCTCTTTG AAACCCAAAATGTCTTCTAAAGAATCAAATTTCTATTTCTGCCTCTGACAAAAAGAACTTACTATGAAAGAAATAGTTGTTTTATCAATA AAAGCCCCTTAATATTATGAAGAAACTTTTCATATTTTTTCTTCTTTATCCTTAATTGTGACTAAGATGGAAATCTAGAAAATATTCATG CTTCTAAGTTTCTGCAGTGTTACTGTAAGAGAGTGTCTCGTCTACACTTCAGTTCTTCTCTCATGTGGAAAACTAAGCTTTTTATATTGA CATTGCCATTGAATAGCTCTAGCAACTATTATTATTCCCCCAAACCCTAAAATTCTACCTATTAGGTGTCAGGTTAAAGTTCTAATTTAT CTTTAGAAATTTATGTGAAAAATGGTTTTCCTATACTGGATAAAGCAATTCCCCTTAGGAAACATAGCCTCAGAGTATTTCATATAAATT TTCTCTATCTAATTCAAACATATCTCCCCATGATACACCGCCAGAGTGACATTGCAGACAGTCTGTGTATGTTTAAATTTTCACTTTTTA TGGATGAGCATAAACCTAGTCTTAGTTTAAAGGCAAACTAAAGTTGAGGGGAAATAATTAATCAATACTGATTAATTGATTTATAAGGTT CAACACTGTCTACCCTAAATAATTTTTATATGCTCAAGGCAAAGCAGGGAATAGAGGCAATTAGCTAGATAATTCAAGCAGAAATCCATT TTCATCGAAATTGCCTGTGTGCACATATTTTTAGATGAAAAATGAAACTACCTTACAATATTATTTTTTTAACCAATGTATTTGTTTGCA AACATTTGCCATGTTGAAGAGTGTGTATAGGAAAGGTCTAGAAATAAATAGGCTTGTGCATACCTAGGCATTCATGCTCTTTCTTCCTCT TCAGAGATCATCAGAAAAGAGGTGGGAATACACAAGCAGGTGCATGTAAGCCCAAAAGCTAGAAAGCCTTATATTTAACCAAAGGTTGAT GTGTTCATTCCAGTTATTCACTTACAGATGAAACTAAAACAAATAAAGGCAAGCTATTATCAGTTTGGTAGTTCATTATTTTAGAACAAA TTTCTAAATTAATTTATTCCCATAACCTACAATAGCACTGAGAACAGAAAACATGTTTCTTCTTCATTTTGTTTAAAGATTGCGTACCTA GGTAAGTCACACTGTATAGATAAAAACCTTCTTCTGTATTCCTCACCTCTAAATTATATGTTATTTGCTATTTGAAAACTGTAGTTAACT ATGGTTTTTTATTAGTCTATTAAAAGATACGTGGAGATATTAAATTATACCTAAAGCAGACGTCCAACAAATTCTGTACATGCTGCTTTA CATCTTTGCAACAAACCTCTTAACTAGCAGCATTATTTCTATAGTGTGATTACCTGAGGGTGCCTCCAAATGTATATCATTTCACTCCCC >12355_12355_2_CACNA2D1-NAALADL2_CACNA2D1_chr7_81964451_ENST00000356860_NAALADL2_chr3_175455094_ENST00000454872_length(amino acids)=261AA_BP=93 MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDIYEKYQDLYTVEPNNARQLVEIAARDIEKLL SNRSKALVLSGEVILQIANEPVLPFNALDIALEVQNNLKGDQPNTHQLLAMALRLRESAELFQSDEMRPANDPKERAPIRIRMLNDILQD -------------------------------------------------------------- >12355_12355_3_CACNA2D1-NAALADL2_CACNA2D1_chr7_81964451_ENST00000423588_NAALADL2_chr3_175455094_ENST00000454872_length(transcript)=3480nt_BP=551nt GCGGCGGAGGCAAGGCGGCCGCGGCGCGGAGCAGCCGACGCACGCTAGTGGGTCCGCCCGCCACCGCCCCTTCCTCGGCGTCCGCTCCCG CCCTTGCCGTCCCCCGCGCGGCTCCGCGCCTCGGGCCCCGGGCGCAGCCAGCCCTCCAGACGCCCGCGGTCCCGGCGGCGTGTGCTGCTC TTCCTCCGCCCGCGGTTTCCAGCGCCGCTCCTTCCCCCGCTTGGGCAGGGAGGGGGCATTGATCTTCGATCGCGAAGATGGCTGCTGGCT GCCTGCTGGCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGCCCCTCGTCGGAGGAGCCGTTCCCTTCGGCCGTCACTATCAAAT CATGGGTGGATAAGATGCAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATTTATGAGAAATATC AAGATTTGTATACTGTGGAACCAAATAATGCACGCCAGCTGGTAGAAATTGCAGCCAGGGATATTGAGAAACTTCTGAGCAACAGATCTA AAGCCCTGGTGCTCTCAGGAGAAGTGATTTTGCAAATTGCCAACGAACCTGTTCTGCCCTTTAATGCACTTGATATAGCTTTAGAAGTTC AAAACAACCTTAAAGGTGATCAACCCAACACTCATCAACTGTTAGCCATGGCGTTACGCCTGCGGGAGAGTGCTGAACTTTTTCAGTCTG ATGAGATGCGACCTGCTAATGATCCCAAGGAGAGAGCACCCATCCGCATCCGGATGCTGAATGACATTCTCCAAGACATGGAGAAAAGCT TTCTGGTAAAGCAGGCACCACCAGGTTTTTATAGAAACATCCTCTACCACCTTGATGAAAAGACAAGCCGGTTTTCAATACTTATAGAGG CTTGGGAACACTGCAAACCCCTTGCATCAAATGAGACCCTTCAAGAAGCCCTGTCAGAGGTGTTGAACAGCATTAATTCAGCTCAGGTTT ACTTCAAAGCAGGACTTGATGTGTTCAAGAGTGTCTTGGATGGGAAGAATTGAGAAAACTCTGAGCATTTTTAAAAGTTTGTTTACAATT CCACAAGCAAAAGCTCTAATTTAACCAGATTTTCTGACATTGAAGGCTTATTTTCCCCAATGGCTTTTTGACAAGTATAAAGCTATTATT ACATTGTATTTTTTAAATGTAAATATAGAAAGAACATTTTGCACATTTAATATTTTTCTTATATCTACATTTCTGAATATGTAAAGCAAG TTATTGAAATAGGACTTAAGAATTACCTATTAAAAAGAAATCTGATATATAAAAATATGTACTATTTTAAGGAAAAATTTCCAAGAAGTT CTGGACTATCTTTGTTCCTATGGGGAGGGCATATAGGAACACAGTTTATTCTCTCTGATAGAGCTATTAATGACTTAGTTTCTGTAAAAG AAATGGAGAGTTGATATGGTTCAGATTAACTTCACTATTAAGTGTTCAATATGAAGAATTCAAGTATTCTGACTGAGTGATTGGTTGACC TAAACCACTTTGAATGTTTCTATTTTATGAAATGAAGTTTCTCTTCTTAACACAACTAGATGTAGTAATACACTGGTTATGAAATTGTAT TTTTTTAAGTATTAATGAAAAAAGAGCCATAAGCATTCCAGGAGAAAATCTCAAGGGAGCTACATAGAGCAATTTAAATGCAAATTTTTT TCCTAACAACTTACAAGGTGACTAGCTTTGAAACCCCTAATTTGCCTCAGTTGATTTTCTAAGAATTTCAGGAGTGATGTATGTCTTAAG AGGGAGAAAAAAATATTTCTTATTACTTTTTCTCTTGTTTCTGTTGGAAACACTGAAGCAGGGACTCTAAAATGAAAGCATCTCACATTG GTTTTCTTTCTTGTATCTTTTCTGAAACTCCTTGCTGTAAGGCAGCTTTCTCAGAGTACTATATATTTTCAACAGTAAAGTAGCAGAGTT TCTCTTTGAAACCCAAAATGTCTTCTAAAGAATCAAATTTCTATTTCTGCCTCTGACAAAAAGAACTTACTATGAAAGAAATAGTTGTTT TATCAATAAAAGCCCCTTAATATTATGAAGAAACTTTTCATATTTTTTCTTCTTTATCCTTAATTGTGACTAAGATGGAAATCTAGAAAA TATTCATGCTTCTAAGTTTCTGCAGTGTTACTGTAAGAGAGTGTCTCGTCTACACTTCAGTTCTTCTCTCATGTGGAAAACTAAGCTTTT TATATTGACATTGCCATTGAATAGCTCTAGCAACTATTATTATTCCCCCAAACCCTAAAATTCTACCTATTAGGTGTCAGGTTAAAGTTC TAATTTATCTTTAGAAATTTATGTGAAAAATGGTTTTCCTATACTGGATAAAGCAATTCCCCTTAGGAAACATAGCCTCAGAGTATTTCA TATAAATTTTCTCTATCTAATTCAAACATATCTCCCCATGATACACCGCCAGAGTGACATTGCAGACAGTCTGTGTATGTTTAAATTTTC ACTTTTTATGGATGAGCATAAACCTAGTCTTAGTTTAAAGGCAAACTAAAGTTGAGGGGAAATAATTAATCAATACTGATTAATTGATTT ATAAGGTTCAACACTGTCTACCCTAAATAATTTTTATATGCTCAAGGCAAAGCAGGGAATAGAGGCAATTAGCTAGATAATTCAAGCAGA AATCCATTTTCATCGAAATTGCCTGTGTGCACATATTTTTAGATGAAAAATGAAACTACCTTACAATATTATTTTTTTAACCAATGTATT TGTTTGCAAACATTTGCCATGTTGAAGAGTGTGTATAGGAAAGGTCTAGAAATAAATAGGCTTGTGCATACCTAGGCATTCATGCTCTTT CTTCCTCTTCAGAGATCATCAGAAAAGAGGTGGGAATACACAAGCAGGTGCATGTAAGCCCAAAAGCTAGAAAGCCTTATATTTAACCAA AGGTTGATGTGTTCATTCCAGTTATTCACTTACAGATGAAACTAAAACAAATAAAGGCAAGCTATTATCAGTTTGGTAGTTCATTATTTT AGAACAAATTTCTAAATTAATTTATTCCCATAACCTACAATAGCACTGAGAACAGAAAACATGTTTCTTCTTCATTTTGTTTAAAGATTG CGTACCTAGGTAAGTCACACTGTATAGATAAAAACCTTCTTCTGTATTCCTCACCTCTAAATTATATGTTATTTGCTATTTGAAAACTGT AGTTAACTATGGTTTTTTATTAGTCTATTAAAAGATACGTGGAGATATTAAATTATACCTAAAGCAGACGTCCAACAAATTCTGTACATG CTGCTTTACATCTTTGCAACAAACCTCTTAACTAGCAGCATTATTTCTATAGTGTGATTACCTGAGGGTGCCTCCAAATGTATATCATTT >12355_12355_3_CACNA2D1-NAALADL2_CACNA2D1_chr7_81964451_ENST00000423588_NAALADL2_chr3_175455094_ENST00000454872_length(amino acids)=261AA_BP=93 MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDIYEKYQDLYTVEPNNARQLVEIAARDIEKLL SNRSKALVLSGEVILQIANEPVLPFNALDIALEVQNNLKGDQPNTHQLLAMALRLRESAELFQSDEMRPANDPKERAPIRIRMLNDILQD -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CACNA2D1-NAALADL2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CACNA2D1-NAALADL2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CACNA2D1-NAALADL2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | CACNA2D1 | C1142166 | Brugada Syndrome (disorder) | 6 | CLINGEN;GENOMICS_ENGLAND;ORPHANET |
Hgene | CACNA2D1 | C0027796 | Neuralgia | 4 | CTD_human |
Hgene | CACNA2D1 | C0038870 | Neuralgia, Supraorbital | 4 | CTD_human |
Hgene | CACNA2D1 | C0042656 | Neuralgia, Vidian | 4 | CTD_human |
Hgene | CACNA2D1 | C0234247 | Neuralgia, Atypical | 4 | CTD_human |
Hgene | CACNA2D1 | C0234249 | Neuralgia, Stump | 4 | CTD_human |
Hgene | CACNA2D1 | C0264893 | Nodal rhythm disorder | 4 | CLINGEN |
Hgene | CACNA2D1 | C0348626 | Other specified cardiac arrhythmias | 4 | CLINGEN |
Hgene | CACNA2D1 | C0423711 | Neuralgia, Perineal | 4 | CTD_human |
Hgene | CACNA2D1 | C0423712 | Neuralgia, Iliohypogastric Nerve | 4 | CTD_human |
Hgene | CACNA2D1 | C0428908 | Sinus Node Dysfunction (disorder) | 4 | CLINGEN |
Hgene | CACNA2D1 | C0751371 | Neuralgia, Ilioinguinal | 4 | CTD_human |
Hgene | CACNA2D1 | C0751372 | Nerve Pain | 4 | CTD_human |
Hgene | CACNA2D1 | C0751373 | Paroxysmal Nerve Pain | 4 | CTD_human |
Hgene | CACNA2D1 | C1399226 | Ectopic rhythm | 4 | CLINGEN |
Hgene | CACNA2D1 | C2748542 | CARDIAC CONDUCTION DEFECT, NONSPECIFIC (disorder) | 4 | CLINGEN |
Hgene | CACNA2D1 | C4551804 | Brugada Syndrome 1 | 4 | CLINGEN |
Hgene | CACNA2D1 | C0020429 | Hyperalgesia | 3 | CTD_human |
Hgene | CACNA2D1 | C0458247 | Allodynia | 3 | CTD_human |
Hgene | CACNA2D1 | C0751211 | Hyperalgesia, Primary | 3 | CTD_human |
Hgene | CACNA2D1 | C0751212 | Hyperalgesia, Secondary | 3 | CTD_human |
Hgene | CACNA2D1 | C0751213 | Tactile Allodynia | 3 | CTD_human |
Hgene | CACNA2D1 | C0751214 | Hyperalgesia, Thermal | 3 | CTD_human |
Hgene | CACNA2D1 | C2936719 | Mechanical Allodynia | 3 | CTD_human |
Hgene | CACNA2D1 | C0003811 | Cardiac Arrhythmia | 1 | GENOMICS_ENGLAND |
Hgene | CACNA2D1 | C0007102 | Malignant tumor of colon | 1 | CTD_human |
Hgene | CACNA2D1 | C0009375 | Colonic Neoplasms | 1 | CTD_human |
Hgene | CACNA2D1 | C0011071 | Sudden death | 1 | GENOMICS_ENGLAND |
Hgene | CACNA2D1 | C0020538 | Hypertensive disease | 1 | CTD_human |
Hgene | CACNA2D1 | C0030193 | Pain | 1 | CTD_human |
Hgene | CACNA2D1 | C0151879 | Shortened QT interval | 1 | GENOMICS_ENGLAND |
Hgene | CACNA2D1 | C0234230 | Pain, Burning | 1 | CTD_human |
Hgene | CACNA2D1 | C0234238 | Ache | 1 | CTD_human |
Hgene | CACNA2D1 | C0234254 | Radiating pain | 1 | CTD_human |
Hgene | CACNA2D1 | C0458257 | Pain, Splitting | 1 | CTD_human |
Hgene | CACNA2D1 | C0458259 | Pain, Crushing | 1 | CTD_human |
Hgene | CACNA2D1 | C0751407 | Pain, Migratory | 1 | CTD_human |
Hgene | CACNA2D1 | C0751408 | Suffering, Physical | 1 | CTD_human |
Hgene | CACNA2D1 | C1865020 | Short QT Syndrome 1 | 1 | ORPHANET |